zilongwang/ReadingBank huggingface dataset:
Table S1. Characteristics of the IR-775 cyanine and Photofrin28–30. Symbol Full name Chemical formula Structural formula Molecular weight [g/mol] IR-775 chloride chloride C32H36Cl2N2 519.55 Photofrin Porfimer sodium 605.69 Table S2. Ratios of (a) the EP effect and (b) the PDT effect for different treatment conditions. a) Treatment LDHe MTT XTT SRB MCF-7/WT MCF-7/DOX MCF-7/WT MCF-7/DOX MCF-7/WT MCF-7/DOX MCF-7/WT MCF-7/DOX IR-775, 2 μM, dark EPDT 1.33±0.12 1.29±0.11 1.91±0.56 1.80±0.74 2.25±0.91 2.15±0.93 2.65±0.84 2.28±0.86 IR-775, 2 μM, EPDT 1.22±0.18 1.34±0.11 2.08±0.65 1.62±0.69 10.32±1.77 1.91±0.77 7.21±0.68 3.38±0.98
1200 ++ 100 ++/+++ 100 ++/+++ 100 NIR 0 ++/+++ 100 ++ 100 ++/+++ 100 1200 +++ disintegration) 100 +++ 100 +++ 100 Photofrin 25 - 0 +/++ 100 + 100 + 100 1200 +/++ 100 + 100 + 100 red 0 ++ 100 ++ 100 +/++ 100 1200 ++ 100 ++ 100 ++ 100 blue 0 ++ 100 ++ 100 +/++ 100 1200 ++ 100 ++ 100 ++ 100 b) Drug Concentration [μM] Irradiation Electric field intensity [V/cm] GST MDR1 MRP7 intensity positive [%] intensity positive cells [%] intensity positive cells [%] - - - 0 - 0 ++ 100 ++ 100 1200 -/+ 100 ++ 100 ++ 90 IR-775 2 - 0 + 100 +/++ 100 ++ 100 1200 ++ 100 ++ 100 ++ 77 NIR 0 + 100 +/++ 100 +/++ 100 1200 ++ 100 ++ 100 +/++ 100 8 - 0 ++/+++ 100 +/++ 100 +/++ 100 1200 +++ 100 ++/+++ 100 ++/+++ 100 NIR 0 ++ 100 +/++ 100 +++ (cell disintegration) 100 1200 +++ (cell disintegration) 100 +++ (cell disintegration) 100 +++ (cell disintegration) 100
(“Vitiligo”[Mesh] OR “Vitiligo”[Tiab]) or “Serum”[Tiab] or “Sera”[Tiab] or “blood”[Mesh] or “blood”[Tiab] or “blood circulation”[Mesh] or “circulat*”[Tiab] or “biomarkers”[Mesh] or “biomarker*”[Tiab]) (“Active“[TIAB] OR “Activity“[TIAB] OR “disease progression”[Mesh] OR “progress“[TIAB] OR “progression”[TIAB] OR “progressions”[TIAB] OR “develop“[TIAB] OR “Stable“[TIAB] OR “Stability“[TIAB] OR “Evoluting“[TIAB] OR “Evolution“[TIAB] OR “Evolve“[TIAB] OR “Evolving“[TIAB] OR “course“[TIAB] or “VIDA”[TIAB]) Search strategy: 1 AND 2 AND 3 Embase Circulating biomarkers (“Vitiligo”/de OR “Vitiligo”:ti:ab) or “serum”:ti:ab or “sera”:ti:ab or “blood”/de or “blood”:ti:ab or “blood circulation”/de or “circulat*”:ti:ab or “biological marker”/de or “biomarker*”:ti:ab) (“Active“:ti:ab OR “Activity“:ti:ab OR “disease course”/de OR “progress“:ti:ab OR “progression”:ti:ab OR “progressions”:ti:ab OR “develop“:ti:ab OR “Stable“:ti:ab OR “Stability“:ti:ab OR “Evoluting“:ti:ab OR “Evolution“:ti:ab OR “Evolve“:ti:ab OR “Evolving“:ti:ab OR “course“:ti:ab or “VIDA”:ti:ab) Search strategy: 1 AND 2 AND 3
LPC (18:2) 520.3398 LPC (18:0) 524.3711 LPE (18:0) 482.3241 LPE (16:0) 454.2928 Glycine 76.0393 Alanine 90.05496 Carnitine 162.1125 Butyrylcarnitine 232.1543 Propionylcarnitine 218.1387 Hexanoylcarnitine 260.1856 Octanoylcarnitine 288.2169 Hexadecanoylcarnitine 400.3421 Octadecadienoylcarnitine 424.3421 Octadecanoylcarnitine 428.3734
Supplemental Table S1: Characteristics of individual patients with eosinophilic gastrointestinal disorders Patient Gender Age at dx (y) BMI Main sx(s) GI tract eosinophil location(s) Therapy Symptom Resolution Endoscopic Resolution Histologic Resolution Histology Details 1 F 10.9 15.8 AP, Di, NV C, D, E MCI, St Yes No Unknown Incr eos in LP; no crypt distortion or other inflammatory cells 2 F 49.2 37.6 AP, Di, NV C, D, E, G LTA, St Yes Unknown Unknown Incr eos in LP and rare crypts of duodenal and colonic biopsies 3 F 82.83 24.0 AP, Co, N G St No Yes Yes Marked incr in gastric mucosal and submucosal eos 4 M 43.92 23.1 Dy G Diet Mod (fish), H2A, LTA, St Yes No No Marked incr in gastric LP and intraepithelial eos 5 F 8.25 16.0 AP D, G Diet Mod, St No Yes No Duodenal focal mild villous blunting, eos dense in LP 6 F 11.42 15.1 AP, Di, V C, E No Unknown Unknown Marked incr in colonic LP eos; 300, 70, 350/HPF in cecum, right, transverse respectively 7 F 0.5 16.4 C, Dy D, G Diet Mod, H2A Yes Yes Yes Incr in LP eos to 50 and 100/HPF in duodenum and stomach respectively 8 M 1.75 15.9 AP, V G Diet Mod (nuts, milk), St Yes Yes Yes Incr antral eos to 20/HPF, focal duodenal lymphoid nodules 9 M 5 27.6 AP, C, Dy, N D Diet Mod, MCI, St No Yes Yes Incr duodenal eos to 70/HPF with overlying ulceration
10 M 12 15.1 AP, C, V D LTA, St Yes Yes No Incr duodenal eos to 40/HPF, degranulated eos and focal enteritis in duodenal biopsy 11 M 2 18.3 AP, C, D, V C, D, E, G Diet Mod, LTA, St No Unknown Unknown Incr gastric eos to 25/HPF, incr to 50 and 30 eos in terminal and tranverse colon with focal lymphoid aggregates 12 M 1.75 14.3 C D H2A, St Yes Yes Yes Incr in duodenal eos to > 100/HPF in LP with eos abscesses and villous blunting 13 M 1.42 15.7 Dy, C, V G Diet Mod, H2A, St Yes Yes Yes Incr in fundic deep LP eos to 30/HPF 14 M 0.83 16.0 D, V G St Yes Yes Yes Incr in gastric LP eos to 25/HPF with chronic gastritis 15 M 10.5 22.3 AP, V C, D, E St Yes No No Incr in duodenal eos to 50/HPF in LP, incr to 75, 50 and 60 eos/HPF in right, transverse, left colon with reactive lymphoid aggregates 16 M 3.83 16.3 AP, C, V G H2A, St Yes Yes Unknown Incr gastric eos to 23/HPF in LP 17 F 13.25 23.6 AP, C, N C, D, E, G LTA, St Unknown No No Incr gastric LP eos to 25/HPF 18 F 16.5 37.9 AP, C, D NV C, E, G H2A, St No Yes Yes Incr antral LP eos to 50/HPF, incr to 40, 75, 75, 75, 50 in terminal ileum, cecal, right, transverse, left colon
Supplementary Table S2: Comparison of symptom resolution Symptoms not resolved N = 27 Symptoms resolved N = 15 Symptom resolution by treatment modality, N (%) Diet modification Mast cell inhibitor H-2 antagonist Leukotriene receptor antagonist Oral corticosteroids Greater than 1 therapy prescribed 12 (44) 1 (4) 12 (44) 4 (15) 22 (81) 21 (78) 7 (47) 1 (7) 5 (33) 1 (7) 12 (80) 11(73) 0.93 0.67 0.49 0.44 0.91 0.75
Welsh onion + + + Common onion + + + Garlic + + + Peanut cv. V5 - Green bean - Mung bean - Soybean cv. DT84 - File 3. CLUSTAL O (1.2.0) multiple sequence alignment between the 640-bp DNA SCAR fragment generated from The Philippines M. graminicola isolate and Contig MiV1ctg921 from M. incognita. The annealing locations of oligonucleotide primers and their orientations are indicated by arrows. File 4. CLUSTAL O (1.2.0) multiple sequence alignment of a 386-bp DNA region including a portion of the 18S rDNA gene, the complete ITS-1 and part of the 5.8S rDNA gene from 36 M. graminicola isolates. >DQ909046.1 >MgVN17 (KF250478)
Molecular formula: C10H15NO Molecular weight : 165.232 pKa : 9.4 Solubility : 7.2 x 104 mg/L Table S2. LC-MS/MS conditions for the analysis of anatoxin-a Compound Precursor ion (m/z) Product ion (m/z) Declustering potential (mV) Collision energy Collision cell exit potential (mV) Anatoxin-a 166 149, 121, 68 61 21 16 Table S3. The quality assurance and quality control (QA/QC) data Compound Retention time (min) Detection limit (n = 7) Recovery (%) LOD LOQ Mean
Supplemental Table S1 Real-Time PCR Primers Gene symbol Genbank ID Primer sequences(5'3') Product size (bp) 18S NR_003286 F: GAGAAACGGCTACCACATCC R: CACCAGACTTGCCCTCCA 170 Vimentin NM_003380 F: ACAGGCTTTAGCGAGTTATT R: GGGCTCCTAGCGGTTTAG 182 -SMA NM_001613 F: CACTGCCGCATCCTCATC R: GCTGTTGTAGGTGGTTTCAT 160 Vimentin NM_003380 F: ACAGGCTTTAGCGAGTTATT R: GGGCTCCTAGCGGTTTAG 182 Calponin NM_001299 F: GCACTGCGACACGCTCAA R: GGGTACTCGGGAGTCAGACAG 129 MMP1 NM_002421 F: TGAAGAATGATGGGAGGCAAGT R: CAGGGTTTCAGCATCTGGTTTC 122 ALP NM_000478 F: CCACAAGCCCGTGACAGA R: GGGCGGCAGACTTTGGTT 127 Runx2 NM_001024630 F: TACCTGAGCCAGATGACG R: AAGGCCAGAGGCAGAAGT 145 OCN NM_199173 F: GGCAGCGAGGTAGTGAAGA R: CCTGAAAGCCGATGTGGT 148
Supplementary Material S.1. Alignments of sequenced bacterial 16S rRNA genes from the end of biodegradation experiments with the alkanolamines DEA and MDEA at 10 and 20°C, and for seawater (SW) incubated at the same conditions. Phylum Class Closest match Similarity (%) Clones (no.) DEA MDEA SW 10°C 20°C 10°C 20°C 10°C 20°C Proteobacteria Alphaproteobacteria Pseudoruegeria aquamaris Hyphomonas jannaschia Hyphomonas sp. Thalassospira lucentensi Thalassospira sp. Sulfitobacter sp. Kopriimonas byunsanensis Zangella mobilis Maritalea myrionectae Erythrobacter citreus Erythrobacter piscidermis Ochrobactrum intermedium Ochrobactrum sp. Phaeobacter arcticus Phaeobacter sp. Silicibacter sp. Roseobacter sp. Therasakiella pusilla Stappia alba Oceanobaculum indicum Parvibaculum lavamentivorans Uncultured Parvibaculum Mycoplana ramosa Brucella suis Thallasobius sp Uncult. Alphaproteobacteria 89 97 99 99 93-97 91-100 89-98 91-95 91 98 99 90 90 97-98 94-98 96 93-99 95 99 89-90 91 90 90 90 94 91-99 1 1 1 4 1 3 1 1 1 1 2 1 1 2 6 2 1 2 4 1 1 1 2 1 2 3 1 2 2 2 2 1 2 2 1 3 1 1 1 3 1 1 1 1 1 5
S.1. Continued. Phylum Class Closest match Similarity (%) Clones (no.) DEA MDEA SW 10°C 20°C 10°C 20°C 10°C 20°C Proteobacteria Betaproteobacteria Denitromonas indolicum 90 1 Deltaproteobacteria Nitrospina sp. Uncult. Desulfobulbus Uncult. Nitrospinaceae Uncult. Deltaproteobacterium 89 90 94-95 88-99 1 1 6 1 6 1 1 4 1 Gammaproteobacteria Methylobacter marinus Uncult. Legionella sp. Uncult. Pseudomonas Uncult. Gammaproteobacteria 90 94 97 92-97 1 1 6 1 1 Actinobacteria Actinobacteria Uncult. Actinobacteria Uncult. Actinomycetes Acidimicrobia 90-99 91 90 3 1 1 1 2 Bacteroidetes Bacteroidia Uncult. Bacteroidetes 96-97 1 1 Cytophagia Uncult. Flexibacter Uncult. Cytophaga 99 95 1 1 2 Flavobacteria Owenweeksia hongkongensis Polaribacter irgensii Polaribacter sp. Aureimarina marisflavi Croceibacter atlanticus Gilvibacter sedimis Uncult.Psychromonas Uncult. Flavobacterium Uncult Flavobacteriaceae 88-90 96-97 97 89-96 99 94 99 94-99 99 4 1 1 1 7 1 2 3 1 1 1 1 1 2 1 3 1 Table S.1. Continued. Clones (no.)
Table 4: Hits returned from refined search terms Ref. No. Number of Results Science Direct Web of Science EBSCO Royal Society of Chemistry 19. 49 7 4 18 20. 34 6 65 25 21. 90 5 28 41 22. 38 9 5 3 23. 29 9 3 5 24. 93 42 3 0 25. 57 0 1 0 26. 7 29 14 0 27. 39 1 1 7 Total: 436 108 124 99 Table 5: List and source of papers screened and reviewed Sector/Theme Number of papers screened Number of papers reviewed Number of high priority papers found EBSCO Science Direct Web of Science RSC EBSCO Science Direct Web of Science RSC Cement 2 41 3 12 2 25 3 7 12 Chemicals manufacturing 26 23 1 0 20 6 1 0 10 Minerals Processing 4 35 6 0 2 14 4 0 8 Refineries 26 23 4 0 16 7 2 0 4 Policy 9 89 1 0 8 35 1 0 15 Pulp and paper 1 30 0 0 1 17 0 0 5 Iron & Steel & Smelting 0 138 45 0 0 55 20 0 17 Food & Drink 0 5 17 0 0 0 4 0 0 Sub-Totals 68 384 77 12 49 159 35 7 71 Total 541 250 71 Table 6: Averaged costs of CCS technologies applied across the industries
Web of Science Title: ((antioxidants OR vitamin e OR ascorbic acid OR carotenoids OR flavonoids OR cysteine OR glutathione) AND (hearing loss OR hearing loss, noise-induced OR hearing loss, sensorineural OR presbycusis OR ototoxicity)) Filter: No patent Circumpolar Health Bibliographic Database; SciELO;The New York Academy of Medicine, ClinicalEvidence.com (antioxidants OR “Vitamin E”OR “ascorbic acid”OR carotenoids OR flavonoids OR cysteine OR glutathione) AND (“hearing loss”OR “hearing loss, noise-induced”OR “hearing loss, sensorineural”OR presbycusis OR ototoxicity)AND (“randomized controlled trial”OR “controlled clinical trial”OR “randomized clinical trial”OR “randomized trial” ) OPENGREY.EU (antioxidants OR “Vitamin E”OR “ascorbic acid”OR carotenoids OR flavonoids OR cysteine OR glutathione) AND (“hearing loss”OR “hearing loss, noise-induced”OR “hearing loss, sensorineural”OR presbycusis OR ototoxicity) AND (“randomized controlled trial”OR “controlled clinical trial”OR “randomized clinical trial”OR “randomized trial”) DissOnline.de “Antioxidantien”AND Hörverlust” Appendix 2 Full texts excluded from the analysis. Source Title Reason Giorgetti Therapeutic effects of Vitamin A associated with vitamin E in perceptual hearing loss 1985 article. Nestrugina Effect of supplementary ingestion of Vitamins B1 and C on the function of the auditory organ in workers of “noisy” trades 1969 article. Creston;Gillespie, 1966 article. Ivstam 1960 article. Mann; Beck; Beck Calcium antagonists in the treatment of sudden deafness. 1986 article. Gordin et al. Antioxidants: a new armament in the treatment of idiopathic sudden hearing loss 2004 article - Requested to the author by email, but without return.
DYS533 4 919 7.94 12.00 DYS570 4 925 10.88 15.65 DYS576 4 926 10.44 15.15 DYS627 4 923 9.90 15.18 DYS635 4 923 7.54 13.38 Y-GATA-H4 4 916 7.75 11.53 (n - 2nt) Stutter DYS19 4 941 7.09 10.11 DYS481 3 934 7.41 9.56 DYS533 4 105 0.74 1.88 DYS627 4 794 1.41 2.71 Plus (n + 1 repeat unit) Stutter DYS19 4 737 1.26 3.72 DYS385 4 883 1.12 3.70 DYS389I 4 271 0.81 3.45 DYS389II 4 551 1.01 3.73 DYS390 4 31 1.19 3.51 DYS391 4 264 0.98 3.41 DYS392 3 936 6.32 11.01 DYS393 4 920 2.07 4.95 DYS437 4 332 0.70 1.65 DYS438 5 42 0.97 2.76 DYS439 4 836 1.24 3.39 DYS448 6 128 0.76 2.29 DYS449 4 845 1.50 4.20 DYS456 4 881 2.03 3.74 DYS458 4 763 0.95 2.52
Duration – destruction of samples & data Your DNA sample(s) will be destroyed and your DNA profile will be removed from the database if the MISSING PERSON listed above is Adapted from UNTCHI/CWAG 61 FR 37495 AABB 2010 BNI 2015
– sample loss Loss of your DNA sample(s) or data is a slight risk. There is also a slight risk that your sample may not yield DNA. In these events you may be asked to provide a new DNA sample. Adapted from ICMP AABB 2010
Confidentiality (LE) – limit of use Your DNA sample will only be used to identify the MISSING PERSON listed above. The AGENCY/ORGANIZATION listed above will not use your DNA to conduct medical testing or for other Adapted from CalDOJ and ICMP Privacy Act of 1974 - 5 USC 552a §2(b)(2)
Confidentiality (LE) – NDIS protections The information you provide for inclusion in the U.S. National Missing Person DNA Database (NMPDD), which is part of CODIS, is protected by the Privacy Act13 notices and the FBI’s Central Authors and adapted from UNTCHI/CWAG 61 FR
Acknowledgment – DNA analysis I authorize the AGENCY/ORGANIZATION listed above to collect my DNA sample for the purpose of identifying my missing family member. Adapted from UNTCHI/CWAG Privacy Act of 1974 - 5 USC 552a §2(b)(1)
Supplement 1. The bedriddenness rank and cognitive function score. Category Criteria Sub category Characteristics i) The bedriddenness rank in daily living for disabled elderly J Slight disorders with being almost independent in daily living and can outing. J1 Use public transport. J2 Go out only neighborhood. A house-bound Almost independent at home without the ability of going out alone. A1 Spend most time away from the bed and sometimes go out with some assistance. A2 Spend most time in bed and rarely go out even with some assistance. B chair-bound Dependent even at home and spend almost time in bed in the daytime with the ability of keeping sitting position alone. B1 Move to wheelchair alone, eat and excrete away from bed. B2 Move to wheelchair with help. C Bedridden and dependent of excretion, eating and gowning. C1 Roll over alone. C2 Roll over with help.
References Number of patients IFX schedule (5mg/kg) Fistula closure rate Side effects Ruemmele FM et al. 2009 (147) n=40 (fistula: n=13) 0, 2, 6 weeks Week 10, 9/13 headache, fever, rash, eczema, neutropenia, muscle pain (n=10) delayed adverse effects (n=3) infection (n=15) Cezard JP et al. 2003 (151) n=21 (fistula: n=12) 0, 2, 6 (n=1; single 1 inj.) Day 90, 12/12 anaphylactic reaction (n=1) Lionetti P et al. 2003 (152) n=22 (fistula: n=7) (fistula + refractory CD: n=6) Reinfusion based on clinical condition Week 18, 7/13 CD, 5/6) (late CD, 2/7) dyspnea, rash, hypotension (n=2 ) de Ridder L et al. 2004 (162) n=30 (fistula: n=16) 0, 2, 6 Reinfusion based on clinical condition 3/16 (6/16 nonproductive fistula) allergic reaction (n=6) death in sepsis (n=1) SupplementaryTable 2. Studies with infliximab administration in pediatric CD patients with fistula (IFX: infliximab, CD: Crohn’s disease)
Supplementary 7. Name Sequence Testis Ex8/9 For 5’ – tcagacgatgcgtcatGAGAGGATCAGGATGCAGTG – 3’ Testis 3UTR Rev 5’ – atgacgcatcgtctgaCCTGTGCCATCTTGCCTAC – 3’ Ex8/9 For 5’ – ctatacatgactctgcGAGAGGATCAGGATGCAGTG – 3’ Brain 3UTR Rev 5’ – gcagagtcatgtatagCCTGTGCCATCTTGCCTAC – 3’ Heart Ex8/9 For 5’ – gatctctactatatgcGAGAGGATCAGGATGCAGTG – 3’ Heart 3UTR Rev 5’ – gcatatagtagagatcCCTGTGCCATCTTGCCTAC – 3’ Muscle Ex8/9 For 5’ – acagtctatactgctgGAGAGGATCAGGATGCAGTG – 3’ Muscle 3UTR Rev 5’ – cagcagtatagactgtCCTGTGCCATCTTGCCTAC – 3’
- Dr. Frédéric Charlate – Physical and Rehabilitation Medicine CRF Jacques Calvé – 47 rue du Docteur Calot 62608 Berck sur mer – France - Dr. Claire Delbrouck – Physical and Rehabilitation Medicine Centre Hospitalier de Cornouaille Concarneau – 61 rue Tregunc 29900 Concarneau – France - Dr. Bernard Coïc – Physical and Rehabilitation Medicine Hôpital Léopold Bellan – 16 rue de l’aqueduc 75010 Paris – France - Dr. Khaled Kayal – Physical and Rehabilitation Medicine Centre de réadaptation de Coubert – Route de Liverdy 77170 Coubert – France - Dr. Isabelle Loiret – Physical and Rehabilitation Medicine Institut Régional de Médecine Physique et de Réadaptation - 75 bd Lobau 54042 Nancy – France - Dr. Brigitte Charton – Physical and Rehabilitation Medicine Centre l’Adapt Thionis – 14 allée de la terrasse 57100 Thionville - France - Dr. Françoise Soulier – Physical and Rehabilitation Medicine Clinique Chantecler – 26 avenue des Poilus 13012 Marseille – France Associated investigators who could not include patients over the period of enrolment - Dr. Robert Lafaye De Micheaux – Physical and Rehabilitation Medicine Institut National des Invalides - 6, boulevard des invalides 75007 Paris – France - Dr. David Rogez - Physical and Rehabilitation Medicine Hôpital d’instruction des Armées Percy - 101, avenue Henri Barbusse 92141 Clamart –France
Supplementary Material: City Risk and Transition Dar es Salaam, Tanzania Critical current climate-related risk Main social drivers Current risk management capacity Key constraints to risk management Urban flooding – very high risk level Urbanization processes and pressures (e.g. inadequate or missing storm-water drainage systems, unregulated housing development particularly in hazardous areas), exacerbated by high rates of Low Population growth greatly outpacing the local governments’ capacity to provide infrastructure and services Sea-level rise and coastal erosion - high risk level, expected to continue to rise as global temperatures rise Economic and recreational opportunities associated with the coastline Fair: city is engaged in awareness-raising and on-the-ground adaptation projects (e.g. construction of sea-walls and groynes along the city centre coastline, mangrove rehabilitation). High and lack of sustained funding (e.g. the sea-wall is donor funded, and currently only for a pilot phase). Heat stress - future climate projections suggest it may have a high risk level Lacking studies. However, likely linked to socio-economic factors that increase vulnerability to heat stress in a range of ways, for e.g., by limited access to cooling systems and energy for these, or by leading to pre-existing health conditions that increase vulnerability to heat stress. Low Limited ability to provide economic opportunities for a growing population. Food security: high risk level, expected to continue to rise as global temperatures rise Increasing agricultural failures in rural areas may further increase rural-urban migration, thus likely increasing competition over scarce food resources Low-medium: Emerging policies account for impacts of climate change on food costs and supply chain. Enhanced social safety nets can support adaptation measures for urban and peri-urban agriculture Poor policy implementation and continued agricultural failures related
Table S2. Microwave Absorption Properties of graphene-based Composites Absorbers Magnetic-material morphology d (mm) Minimum RL (dB) Peak location (GHz) Bandwidth (Range, GHz) Test temperature Ref. RGO/Bi2Fe4O9 Microsphere 2.00 -71.88 13.8 11.92-16.16 298K 16 ZnO-Ni-C/RGO yolk-shell 2.05 -59.30 15.2 12.40-18.00 298K 17 CoFe2O4/RGO Particle 1.60 -46.80 11.6 10.00-13.44 298K 18 Co2Z/RGO Plate 2.00 -35.20 14.7 12.00-16.24 298K 19 Co3O4/RGO Nanosheet 3.60 -45.15 10.5 8.31-13.92 298K 13 Co3O4-rGO Micro flower 2.40 -61.00 11.2 9.60-13.40 298K This work 1.8-1.9 -38.30 12.1 8.30-12.40 353-473K References [1] C.Z. He, S. Qiu, X.Z. Wang, J.R. Liu, L.Q. Luan, W. Liu, M. Itoh, K. Machida, Facile Synthesis of Hollow Porous Cobalt Spheres and Their Enhanced Electromagnetic Properties, J. Mater. Chem. 22 (2012) 22160-22166. [2] X.L. Shi, M.S. Cao, J. Yuan, X.Y. Fang, Dual nonlinear dielectric resonance and nesting
Table D2 Export and IPC (all coefficients) Linear FE SW FE Tobit FE IPCit −0.375 −0.336 −1.689 (0.198)* (0.128)*** (0.862)** FBi∙IPCit −2.387 −2.426 −3.182 (1.246)* (0.66)*** (1.294)** Sales 2.40e-08 −1.12e-09 (6.40e-08) (8.99e-08) R&Dd 0.052 0.673 (1.128) (3.028) R&Df −0.586 −0.579 (0.790) (2.555) R&Dc −1.445 −1.551 −8.989 (0.859) (0.582)*** (3.459)*** OW 0.075 0.067 0.303 (0.066) (0.031)** (0.193) Age 0.006 0.17 (0.067) (0.119) IC 2.126 10.624 (2.567) (8.770) CC 0.822 0.829 2.603 (0.916) (0.472)* (2.877) IF −0.014 −0.002 (0.018) (0.052) PW 0.008 −0.012 (0.022) (0.036) NPW 0.054 0.051 0.137 (0.026)* (0.01)*** (0.060)** TW 0.01 −0.013 (0.037) (0.040) TR 2.305 2.573 14.979 (1.445) (1.213)** (7.319)** Year = 2005 −1.017 (0.819) Constant −8.725 (136.289) Observations 917 917 Standard errors in parentheses. Significant at: *10%; ** 5%; *** 1%. D3
Figure S1. Pareto charts of standardized effects for (a) Cd(II), (b) Cu(II) and (c) Fe(II) ions adsorption onto Pec-CF beads. Table S2. Analysis of variance (ANOVA) for Cd(II) removal. Source Degrees of freedom Sum of squares Mean squares F-cal F-tab Regression 3 67.02 22.34 21.47 2.56 Residues 13 13.53 1.04 Total 16 80.54 Note: F0,05; 3; 13 = 2.56 (R2 = 0.832) Table S3. Analysis of variance (ANOVA) for Cu(II) removal. Source Degrees of freedom Sum of squares Mean squares F-cal F-tab
where KL is the Langmuir isotherm constant (L/mg) and C0 is the initial metal concentration (mg/L). Figure S8. Amount of metal adsorbed per gram of Pec-CF beads (qe) in consecutive adsorption/desorption cycles.
S1. Specific primer sets used for Gnomoniopsis castanea molecular identification Gene Primer name Primer sequence Annealing Reference Elongation factor 1-α EF1-728F 5’-CATCGAGAAGTTCGAGAAGG-3’ 58 °C Carbone and Kohn, 1999 EF1-1199R 5-’GGGAAGTACCMGTGATCATGT-3’ Walker et al., 2010 RNA polymerase II 5F GGGGWGAYCAGAAGAAGGC 50 °C Liu, Whelen, & Hall (1999) 7CR CCCATRGCTTGYTTRCCCAT β-tubulin T1 56 °C O’Donnell and Cigelnik, 1997 T2 5’-AACATGCGTGAGATTGTAAGT-3’ ITS ITS1 5’-TCCGTAGGTGAACCTGCGG-3’ 55 °C White et al., 1990 ITS4 5’-TCCTCCGCTTATTGATATGC-3’
Figure S10. Internal resistance (IR) voltage drops of the SASCs versus current density. Figure S11. The enhanced mechanism of the α-Fe2O3/C electrode. Table S1. Element percentage of α-Fe2O3/C nanoarrays from the EDX spectra. Z Element Family Atomic Fraction (%) Atomic Error (%) Mass Fraction (%) Mass Error (%) Fit error (%) 6 C K 33.71 4.31 18.10 1.65 0.97 7 N K 1.93 0.46 1.19 0.26 1.71 8 O K 42.22 10.01 30.74 6.75 0.22 26 Fe K 22.13 4.08 49.98 8.04 0.08 Table S2. Element content of α-Fe2O3/C nanorods from the XPS analysis Element Atomic Conc % Iron 27.44 Oxygen 54.77 Nitrogen 0.58 Carbon 17.22 Table S3. Comparison of electrochemical performance of Fe2O3-based electrodes Material Potential Window Specific Capacitance Cycle Life Retention Ref α-Fe2O3/C Nanoarrays -1-0 V vs Ag/Ag Cl 391.8 F g-1 at 1.25 A g-1 (431.0 F cm-2 at 1 mA 91.8% after 4000 cycles This work
Supplementary Online Contents Supplemental 1. Study patients in 26 centers Institution (n) Analysis (n) CT scanner 1 Hiroshima University 719 708 GE VCT 64 2 Kindai University 332 319 GE VCT64 3 Shin-Koga Hospital 300 296 GE VCT64 4 Juntendo University 275 270 Toshiba Aquilion64 5 Hiroshima General Hospital 169 160 GE VCT64 6 Kure Kyosai Hospital 115 114 Siemens DEFINITION 7 Megumino Hospital 108 105 Siemens DEFINITION 8 Fujisawa City Hospital 101 98 GE VCT64 9 Tsuchiya General Hospital 109 96 GE VCT64 10 Takase Clinic 97 94 Toshiba Aquilion ONE 11 Atomic Bomb Casualty Council Health Management & Promotion Center 82 82 GE VCT64 12 Yokkaichi Hazu Medical Center 76 67 Toshiba Aquilion ONE 13 Hiroshima City Asa Hospital 78 69 Siemens DEFINITION 14 Kokura Memorial Hospital 85 59 GE 15 Uwajima City Hospital 53 49 GE VCT64 16 Nippon University 50 50 Toshiba Aquilion ONE 17 Tokyo Medical University 100 40 GE VCT64 18 Kyorin University 53 39 Siemens DEFINITION 19 Shizuoka Prefecture General Hospital 43 35 GE VCT 64 20 Osaka Ekiseikai Hospital 32 22 Siemens DEFINITION 21 Yamaguchi University 16 14 Siemens DEFINITION 22 Mitsui Memorial Hospital 8 6 Toshiba Aquilion ONE 23 Ehime University 6 5 Siemens DEFINITION 24 Morishita Clinic 4 4 Siemens DEFINITION 25 Nippon University Hospital 3 3 Siemens DEFINITION 26 Itabashi Central Hospital 1 1 Toshiba Aquilion 64 Total 3015 2802
Are there high contrast colours to indicate different heights? Yes No Are the colours of the surfacing material different within and outside a fall zone? HINT: the fall zone is the area under and around a piece of equipment where a child might land or exit that equipment. Yes No *Any safety concerns (e.g. rust, maintenance issues in play equipment and play area)? Other comments Pre-School Playground. Sensory stimulation/Play richness (Please circle how accessible are they for the following?) Vestibular stimulation Spinning Yes No Sliding Yes No Sliding- the ability to slide two people side by side Yes No Rocking Yes No Swing – Presence of full body support swing (e.g. nested swing) Yes No Climbing/Crawling Yes No Visual stimulation Is there equipment which provides visual stimulation (coloured lights/mirrors/black and white) Yes No Olfactory stimulation Plants/herbs to stimulate smell Yes No Tactile stimulation Is there play equipment providing opportunities for tactile stimulation (rocks/sand/dirt/water/rice/grass/mirrors/marbles) Yes No Auditory stimulation Is play equipment providing auditory stimulation (echoes/chimes/talking tubes) Yes No
ONLINE APPENDIX Supplementary Methods Pulse sequence parameters and CMR protocol Cine imaging used a balanced steady-state free precession (bSSFP) pulse sequence (echo time (TE)/repetition time (TR)/flip angle 1.3ms/2.6ms/40°, spatial resolution 1.6×2.0×10mm, typical temporal resolution 25ms). Tissue tagging used a spatial modulation of magnetization (SPAMM) pulse sequence (spatial resolution 1.5×1.5×10mm, tag separation 7mm, temporal resolution ≤35ms, typical TR/TE/flip angle 5.9/3.5/10°). T2-weighted imaging used a dark-blood T2w fast spin echo short tau inversion-recovery (STIR) sequence (TE 90 ms, TR two R-R intervals, flip angle 90 degrees, spatial resolution 1.7×1.7×10 mm) and constant level appearance (CLEAR) homogeneity correction. T1 mapping used a 17-heart MOLLI method to acquire 11 images (3-3-5 acquisition with 3x R-R interval recovery epochs) in a single end-expiratory breath hold (1,2) (bSSFP readout in end-diastole, manual RF shim adjustments, 2x sensitivity-encoded (SENSE) acceleration, acquired spatial resolution 1.7×2.1×10mm, typical TE/TR/flip angle 2.7/1.06/35°). 0.1mmol/kg gadolinium-DTPA (gadopentetate dimeglumine; Magnevist, Bayer, Berlin, Germany) was then administered using a power injector (Spectris, Solaris, PA). Repeat MOLLI T1 mapping was performed at 15 minutes post-contrast, and LGE imaging at 16-20 minutes post contrast (inversion recovery-prepared T1-weighted gradient echo, inversion time according to Look-Locker scout, spatial resolution 1.54×1.75×10mm, TR/TE/flip angle 3.7/2.0/25°). In addition to the three LGE short-axis slices for analysis, a contiguous stack of LGE images was acquired immediately after the three slice LGE acquisition (imaging parameters as above, slice thickness 10mm, no slice gap).
Universitätsklinikum Tübingen Tübingen, Germany Dominik Ketelsen Royal Prince Alfred Hospital Sydney, Australia Steven Dubenec Luzerner Kantosspital Luzern, Switzerland Martin Banyai Hôpitaux Universitaires de Strasbourg - Hôpital Civil Strasbourg, France Nabil Chakfe Landesklinikum Thermenregion Mödling Mödling, Austria Franz Xaver Roithinger Università Cattolica del Cuore Policlinico Gemelli Rome, Italy Carlo Trani As-Salam International Hospital Cairo, Egypt Hossam Mansour Korea University Guro Hospital Seoul, South Korea Seung-Woon Rha Universitair Ziekenhuis Gent Gent, Belgium Frank Vermassen Rabin Medical Center - Beilinson Hospital Petach Tikva, Israel Alexander Belenky VUSCH Kosice, Slovakia Lubomir Spak Manchester Royal Infirmary Manchester, United Kingdom Nicholas Chalmers Centre Hospitalier Universitaire de Sherbrooke (CHUS) Sherbrooke, Canada Andrew Benko Changi General Hospital Singapore Steven Kum Ajou University Hospital Seoul, South Korea Je Hwan Won SUSCCH Banská Bystrica, Slovakia Matej Vozar Toronto General Hospital Toronto, Canada Kong Teng Tan Egypt Air Hospital Cairo, Egypt Mamdouh Labib Universitair Medisch Centrum Utrecht Utrecht, The Netherlands Gert-Jan de Borst Samsung Medical Center Seoul, South Korea Young-Soo Do Catharina Ziekenhuis Eindhoven, The Netherlands Joep Teijink Clinica Santa Maria Medellin, Antioguia, Columbia Juan Fernando Gomez
Supporting information of Liquid Organic Hydrogen Carriers Teng Hea,*, Qijun Peia,b, Ping Chena,c,* a. Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, Liaoning, China b. University of the of the Chinese Academy of Sciences, Beijing 100049, China c. State Key Laboratory of Catalysis, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457, Zhongshan Road, Dalian 116023, Liaoning, China * Corresponding author: Tel: +86 411 84379583; Fax: +86 411 84379905 E-mail: (T. He); (P. Chen); Data in Figure 5 Number Organic hydrogen carriers Hydrogen capacity (wt%) ΔH(kJ mol-1 H2) 1 2,3-dihydro-1H-phosphindol-1-ol 1.3 71.4 2 2,3-dihydro-1H-benzo[b]silole 1.5 68.9 3 Tetracosahydrocoronene 7.4 54.6 4 cyclopentane 5.7 105.5 5 Cyclohexane 7.1 68.6 6 Methylcyclohexane 6.1 68.3 7 Decalin cis trans 7.2 63.4 66.4 (63.9) 8 Bicyclohexyl 7.2 67.2 9 pyrrolidine 5.6 55.4 10 piperidine 7.1 63.8 11 4 40.7 12 octahydro-1H-purine 6.3 26.9 13 6.6 32.3 14 Imidazolidine 5.6 39.9 15 Hexahydropyrimidine 7 60.1 16 Dodecahydrocarbazole 6.7 51.2
17 Dodecahydro-N-ethylcarbazole 5.8 50.8 18 Indoline 1.7 52.1 19 4-Aminopiperidine 6 55.9 20 1,2,4-triazolidine 5.5 26.5 21 1,2,3-triazolidine 5.5 22.3 22 1-methylimidazolidine 4.7 39.1 23 cyclohexanol 6 61 24 tetrahydrofuran 5.6 77 25 tetrahydrothiophene 4.5 76.6 26 HCOOH formic acid 4.3 31.5 27 CH3OH+H2O methanol 12 43.8 28 CH3CH2NH2 ethylamine 8.9 57.4 29 dodecahydro-1H-dibenzo[b,d]borole 6.8 42.8 30 dodecahydrodibenzo[b,d]furan 6.7 56.7
Supplementary Materials -- Appendix Table. City Membership by Type. Table S1. City Membership by Type. Typological Membership Continent Type 1 37 Cities Type 2 29 Cities Type 3 26 Cities Type 4 28 Cities Type 5 7 Cities Type 6 15 Cities Africa Accra Addis Ababa Cape Town Casablanca Dar es Salaam Kinshasa Lagos Nairobi Tripoli Tunis Johannesburg Abuja Durban Cairo Asia Amman Ankara Bangalore Bangkok Chennai Damascus Delhi Dhaka Ho Chi Minh City Hyderabad Jakarta Karachi Kolkata Mumbai Riyadh Sana'a Surabaya Tehran Yangon Bishkek Colombo Islamabad Jerusalem Phnom Penh Quezon City Ulaanbaatar Bandar seri begawan Beirut Cebu Naihati Beijing Guangzhou Istanbul Nagoya Osaka Seoul Shanghai Shenzhen Singapore Tashkent Tokyo Yokohama Abu Dhabi Doha Kuwait City Manama Kathmandu Kuala Lumpur Manila Vladivostok Australia Melbourne Sydney Europe Berlin Madrid Athens Barcelona Bucharest Budapest Chisinau Hamburg Lisbon Paris Prague Riga Vienna Warsaw Bern Brussels Copenhagen Geneva Hanover Helsinki Ljubljana Sarajevo Vilnius Kiev London Moscow Rome St. Petersburg Amsterdam Dublin Minsk Sofia Stockholm Tbilisi
North America Guadalajara Santo Domingo Anchorage Boston Kingston Port-of-Spain Portland Seattle St. John's Chicago Los Angeles Mexico City Montreal New York Toronto Vancouver Phoenix Denver Detroit Ottawa Victoria South America Bogota Caracas Lima Santiago Sao Paulo Belo Horizonte Brasilia Curitiba Guatemala City Montevideo Quito Asuncion Florianopolis Panama City San Salvador Buenos Aires Cali
Since the current and voltage output on the resistor is the differential of QA and QB by t, the calculated current and voltage output will be independent of the choice of charge reference state. Similarly, if the periodic boundary condition is utilized to solve the equation, the calculated current and voltage output will also be independent of the choice of charge reference state. 1.4 Minimum Achievable Charge Reference State (MACRS) The most commonly utilized charge reference state is called minimum achievable charge reference state, which utilizes the amount of charge on metal 2 under SC condition when x = 0 as Q0 (which is also the minimum achievable amount of charges on metal 2 under real operation). The main advantage to utilize the minimum achievable charge reference state is to set both QSC(x=0) and VOC(x=0) to 0 and this time QSC stands for the total transferred charges amount from one electrode to another under SC condition. FEM results from other charge reference states can be easily converted to the MACRS. From the above derivation, we can easily get the below conversion equation. 1.5 Symmetric charge reference state in FTENGs The minimum achievable charge reference state is the most commonly utilized charge reference state, but in FTENGs, utilizing this charge reference state will cause the calculated VOC nonsymmetrical. However, an inherent symmetry can be easily observed in the structure for both contact-mode FTENGs and sliding-mode FTENGs. The reason that the calculated VOC are nonsymmetrical under MACRS mainly because the amount of charges assigned on metal 1 and metal 2 are different. To maintain the symmetry, we can assign both metal 1 and metal 2 have the same amount of charges (σwl/2). Then the calculated VOC will be fully symmetric. Figure S1 shows the FEM calculation result of VOC under symmetric charge
capacitance of MoO3-GAs shows a decrease to 373 F g−1 at a scan rate of 200 mV s−1 from 636 F g−1 at 1.0 mVs−1. Furthermore, upon increasing the current density up to 10.0A g−1 from 1.0 A g−1, the specific capacitance of MoO3-GAs decreased only slightly to 210 F g−1 from 275 F g−1. Figure S9 (a) SEM image of MoO3 powders. (b) CV curve of MoO3 electrodes at the scan rate of 50 mV s−1. (c) Galvanostatic charge/discharge curves at a current density of 0.05A g−1.(d) Cycling stability of the MoO3 electrode at a current density of 0.05A g−1. Figure S10 Nyquist plots of the MoO3-GAs and GAs. The inset shows the equivalent circuit. Cd is double-layer capacitance, Rct is charge-transfer resistance, Zw is the Warburg impedance, and Rs represents the internal resistance of the electrodes. Figure S11 (a) SEM image, (b) Low and (c) high resolution TEM images and (d) Raman of MoO3-GAselectrode after cycling performance. Figure S12 Ragone plot of the MoO3-GAs electrode in 1 M H2SO4 aqueous solution. Figure S13 a) CV curves of GAs, L-MoO3-GAs, MoO3-GAs and H-MoO3-GAs electrodes measured at the scan rate of 50 mV s−1. b) CV curves of the H-MoO3-GAs electrode at 50 mV s −1of the 1st, 40th and 100th cycle. SEM images of (c) L-MoO3-GAs and (d) Figure S14 Cycling stability of MoO3-GAs electrode at a current density of 10.0 A g−1. Figure S15 Nitrogen adsorption/desorption isotherms of (a) the MoO3-GAs and (b) The specific surface area was 147.5 m2 g−1 for GAs, and 154.6 m2 g−1 for MoO3-GAs.
C-Z8 2.59 94.47 2.78 - 0.16 a Tested by XPS Table S3 A comparison of ORR activity in acidic electrolyte for Fe-N-C catalysts reported before and newly prepared in this work. Materials potential (V vs. RHE) Half-wave potential (V vs. RHE) H2O2 yield (%) (0.1-0.8 V vs. RHE) Mass activity at 0.8 V vs. RHE Ref Catalysts derived from heterometal-embedded organic conjugate frameworks 0.90 0.76 - - Carbon nanotube sponge catalysts 0.86 0.68-0.7 - - PANI-Fe-C 0.92 0.80 ~1 6.7 Non-precious metal electrocatalysts prepared from zeolitic imidazolate frameworks 0.914 0.78 <8.5 4.0 Nitrogen-doped carbon architectures with iron carbide encapsulated in graphitic layers 0.92 0.77 <1.8 - Nitrogen-doped hierarchically porous carbon 0.90 0.70-0.72 <1.87 - Phenylenediamine-based FeNx/C catalyst 0.92 0.82 <4 11.5 graphitic architectures 0.88 0.74 - - S-Doping Fe/N/C ORR Catalyst - 0.836 - 23 GNTs with a Biomimetic Heme Model Compound - 0.88 <1 2.66 (@ 0.9 V)
ITO Glass/Nb2O5/PSC (0.25 cm2) Reversed scan 22.22 1.04 60.5 13.98 PET ITO/Nb2O5/PSC (0.09 cm2) Forward scan 23.5 1.12 63.1 15.56 PET ITO/Nb2O5/PSC (0.09 cm2) Reversed scan 23.25 1.12 57.7 15.02 PET ITO/Nb2O5/PSC (0.25 cm2) Froward scan 22.93 1.0 61.2 14.04 PET ITO/Nb2O5/PSC (0.25 cm2) Reversed scan 22.82 1.0 61.3 13.98
S.6. Force Sensitive Resistor (FSR) Force measured depends on the resistance of the FSR. Resistance of FSR decreases with increase in force applied. Circuit diagram Calibration of FSR for various force (N) FSR Resistance in K Ω) (FSR + R)K Ω Current through FSR+R in mA Voltage across R in V Infinite Infinite! 0 0 0.2 30 40 0.13 1.3 1 6 16 0.31 3.1
N,S-3DPG N,S co-doping; 3D network; structure; porous structure lyophilization and pyrolysis 1 M KOH 1.45 1.54 68.3 This carbon nitrogen nanotubes (N-CNT) N doping liquid CVD 0.1 M KOH 1.50 1.68 383 11 N-doped G (N-G) N doping pyrolysis of GO and polyaniline 0.1 M KOH 1.41 1.62 / 12 oxidized carbon (O-C) O doping acidic oxidation 0.1 M KOH 1.45 1.72 82 13 B CNTs (B-CNT) B doping CVD 1 M KOH 1.65 1.83 / 14 N,O co-doped carbon hydrogel film (N,O-C) electrode structure; N,O co-doping layer-by-layer assembly 0.1 M KOH 1.31 1.63 141 15 N,S co-doped G (N,S-G) pyrolysis N,S co-doping 0.1 M KOH 1.52 1.65 59 16 co-doped G/carbon nanosheets (N,P-C) N,P co-doping pyrolysis 0.1 M KOH 1.32 1.57 70 17 N,O,P tri-doped porous carbon N,O,P pyrolysis 1 M KOH 1.52 1.63 84 18 N-doped G/CNTs hybrids (N-G/CNT) composites of carbon allotropes; N doping CVD 0.1 M KOH 1.45 1.63 83 19 g-C3N4/G composites of g-C3N4 and graphene 0.1 M KOH 1.58 1.81 68.5 20 Note: G stands for reduced graphene oxide (also graphene). CNT stands for carbon
nanotubes. "/": the data was not given. Carbon-fiber paper: CPF. All the potentials are calibrated and converted to reversible hydrogen electrode. S2. Comparison of materials, characteristics, preparation methods, specific performance of N,S-3DPG with the reported carbon-based HER catalysts in alkaline medium. Samples Characteristics methods Electrolyte Onset potential (V) Potential at 10 mA cm−2 (V) Tafel slope value mV dec-1 Ref. N,S-3DPG N,S co-doping; 3D network structure; porous structure lyophilization and pyrolysis 1 M KOH 0.19 0.28 68.4 This work N-rich graphene monoliths N doping; holey structure pyrolysis 0.1 M KOH 0.30 0.51 157 21 N, P Co-doped carbon networks N,P Co-doping; 3D network pyrolysis 0.1 M KOH 0.29 0.47 / 22 N, P co-doped nanoporous graphene N,P Co-doping; porous structure bottom-up approach (annealing) 0.1 M KOH 0.35 >0.6 / 23 N,O,P tri-doped porous carbon N,O,P Co-doping pyrolysis 1 M KOH 0.28 0.45 154 18 g-C3N4@N-doped graphene g-C3N4/graphene composites; N doping lyophilization and pyrolysis 0.1 M KOH 0.35 >0.6 / 24 g-C3N4–S,Se graphene g-C3N4/graphene composites; S, Se co-doping lyophilization andpyrolysis 0.1 M KOH 0.45 1.1 93 25 g-C3N4–N,P graphene g-C3N4/graphene composites; N, P co-doping lyophilization and pyrolysis 0.1 M KOH 0.45 0.58 129 26 Table S3. Comparison of ORR electrocatalytic performance of N,S-3DPG with some
2010, 5, 651 Graphene > -70o N/A 0.42 No Gel Nat. Commun. 2013, 4, 2487 Graphene quantum dots ~ -75o N/A < 0.2 No Liquid Adv. Funct. Mater. 2013, 23, 4111 CNT/Graphene -81.5o 0.195 0.82 No Liquid Nano Lett. 2013, 13, 72 RGO/CNT > -60o N/A 3.4 No Liquid Adv. Funct. Mater. 2012, 22, 4501 SWCNT N/A N/A 162 30% Gel ACS Nano 2013, 7, 7975. SWCNT film -75.2o 0.2 1.2 200% Gel This work PEDOT: Poly(3,4-ethylenediox-ythiophene); RGO: Reduced graphene oxide.
Figure S5. The absorbance of TiO2, SnO2, and stacked n-layer based perovskite films. Figure S6. The detailed statistics of Voc, Jsc, and FF decays over time. Figure S7. X-ray diffraction pattern of SnO2 nanoparticles. The diffraction peaks from each crystal planes are labelled. Figure S8. FT-IR of SnO2 at 30 ℃, 150 ℃, 300 ℃, respectively. Figure S9. Commercial environmental chamber for accelerated stability tests.
method. Characterizations and performance measurements. The morphological features of the samples were examined by SEM (FEI Nova-450). The photovoltaic performances of the PSC unit were measured under simulated AM1.5 G illumination (1 sun, 100 mW cm-2) provided by a solar light simulator (Oriel Solar Simulator, Model 91160). The current-voltage characteristics were recorded by a Keithley 2400 source meter. The IPCE spectra were measured as a function of wavelength controlled by a monochromator. The active area of the PSC in this study is 0.1 cm2. The CV and galvanostatic charging-discharging curves of the supercapacitor unit were evaluated on a Chenhua CHI-760 electrochemical workstation. The photocharging/galvanostatic-discharging characteristics of the solar capacitors were evaluated under continuous simulated solar illumination. The areal specific capacitance (C) and energy density (E) of the supercapacitor unit were calculated by the following equations: where I, S, ∆t, and ∆V represent the applied discharge current, the area of the electrode, the discharge time, and the potential window, respectively. Table S1. Performances of representative photo-chargeable solar capacitors in the literatures. References Photovoltaic unit Energy storage unit Voltage plateau (V) η (%) This work All-inorganic PSC All-inorganic Supercapacitor 1.2 5.1 [30] Organic-inorganic PSC Polymer electrolyte Supercapacitor 0.70 -- [35] Organic-inorganic PSC Liquid electrolyte based Supercapacitor 0.70 4.7
[27] Organic polymer solar cell Polymer electrolyte based Supercapacitor 0.40 0.8 [38] Organic polymer solar cell Polymer electrolyte based Supercapacitor ~0.6 -- [41] Quantum Dot Solar Cell Liquid electrolyte based Supercapacitor ~0.16 -- [26] DSSC Liquid electrolyte based Supercapacitor 0.62 2.1 [28] DSSC Polymer electrolyte Supercapacitor 0.64 2.1 [29] DSSC Polymer electrolyte based Supercapacitor 0.70 1.8 [31] DSSC Liquid electrolyte Supercapacitor 0.60 1.6 [34] DSSC Polymer electrolyte based Supercapacitor 0.65 1.8 [36] DSSC Polymer electrolyte Supercapacitor 0.60 1.5 [37] DSSC Liquid electrolyte based Supercapacitor 0.8 -- [39] DSSC Polymer electrolyte based Supercapacitor 0.63 1.2 Figure S1. Typical SEM images of the surface morphologies of (a) c-TiO2 layer, (b) m-TiO2 layer, (c) CsPbBr3 film and nanocarbon electrode. Figure S2. XRD pattern of CsPbBr3 film in the all-inorganic PSC without the nanocarbon layer.
Not Applicable Missing 309 (11.3%) 34 (1.2%) 2,725 “How often has your provider been supportive of your weight concerns and efforts to be healthy?” Frequently Sometimes Never Don’t Remember Not Applicable Missing Total 1,067 (39.2%) 620 (22.7%) 399 (14.6%) 235 (8.6%) 363 (13.3%) 41 (1.5%) 2,725 “Does your provider understand the physical and emotional challenges by people who are overweight or obese?” No Yes Not Applicable Don’t Know Missing 247 (9.1%) 1,416 (52.0%) 479 (17.6%) 462 (16.9%) 121 (4.4%) 2,725 Items represented in Figure 2 “How often has your provider brought up the issue of weight at any clinic visit?” Frequently Sometimes Never Don’t Remember Not Applicable Missing Total 710 (26.1%) 1,149 (42.2%) 629 (23.1%) 161 (5.9%) 57 (2.1%) 19 (0.7%) 2,725 “Has your provider ever discussed or given you resources on healthy eating and weight loss?” No Yes Don’t Know Missing Total 688 (25.2%) 1,627 (59.7%) 323 (11.9%) 87 (3.2%) 2,725 “Has your provider offered information or advice on healthy eating and weight loss that was not helpful?” No Yes Don’t Know Missing Total 1,854 (68%) 345 (12.7%) 465 (17.1%) 61 (2.2%) 2,725 “Has your provider discussed or given you info about dietary or physical activity or lifestyle changes?” No Yes Missing Total 121 (7.4%) 1,452 (89.2%) 54 (3.3%) 1,627 “Has your provider discussed or given you info about weight loss classes or programs?” No Yes 503 (30.9%) Yes (63.3%)
Missing Total 94 (5.8%) 1,627 “Has your provider discussed or given you info about prescription weight loss medication?” No Yes Missing 1,340 (82.4%) 171 (10.5%) 116 (7.1%) 1,627 “Has your provider discussed or you info about meal replacement?” No Yes Missing Total 1,181 (72.6%) 325 (20.0%) 121 (7.4%) 1,627 “Has your provider discussed or given you info about surgery?” No Yes Missing 1,273 (78.2%) 238 (14.6%) 116 (7.1%) 1,627 Represented in Figure 3 “Do you wish your provider discuss healthy eating and weight loss strategies with you?” No Yes Sometimes Don’t Know Missing Total 935 (34.3%) 766 (28.1%) 934 (34.3%) 7 (0.3%) 83 (3.1%) 2,725 “Do you wish you had more info or access to dietary or physical activity or lifestyle changes?” No Yes Missing Total 1,264 (46.4%) 1,255 (46.1%) 206 (7.6%) 2,725 “Do you wish you had more info or access to weight loss classes or programs?” No Yes Missing Total 1,349 (49.5%) 1,164 (42.7%) 212 (7.8%) 2,725 “Do you wish you had more info or access to prescription weight loss medication?” No Yes Missing Total 1,602 (58.8%) 916 (33.6%) 207 (7.6%) 2,725 “Do you wish you had more info or access to meal replacements?” No Yes Missing Total 1,578 (57.9%) 923 (33.9%) 224 (8.2%) 2,725 “Do you wish you had more info or access to surgery?” No 1,981 (72.7%)
Table S1. Information about the target compounds chosen for this study Order Compounds Short MW Boiling point Formula CAS Odor name (g mol-1) °C number Threshold (ppb)a 1 Hydrogen sulfide H2S 34.1 -60.0 H2S 7783-06-4 0.41 2 Methyl mercaptan CH3SH 48.1 5.95 74-93-1 0.07 3 Dimethyl sulfide DMS 62.1 35.0 (CH3)2S 75-18-3 3.00 4 Dimethyl disulfide DMDS 94.2 110 (CH3)2S2 624-92-0 2.07 aRefer to Nagata (2003)
Review Marine biotoxins and associated outbreaks following seafood consumption: prevention and surveillance in the 21st century Supplementary data: Types of poisoning and description of outbreaks 2. 2 CFP: ciguatoxins (CTXs), maitotoxins (MTXs), gambierol Europe Two clusters of CFP occurred in (France) in 2001. Both were related to consumption of Sphyraena barracuda and Lutjanus griseus caught in Guadeloupe (French West Indies). The first one involved 8 persons and the second two individuals. According to the authors, the presence of CTXs in both incidents was also suspected by the use of an MBA protocol specifically designed for the detection of toxicity due to ciguatoxins (). Based on visual observations of the mice (death time, loss in body weight) it could be concluded that the levels of ciguatoxin were the highest in the barracuda. Eleven fishermen got intoxicated and showed symptoms typical of those of ciguatera after consumption of Seriola spp. caught at the Selvagens Islands (Madeira, Portugal). While no information on the levels of CTXs present in the above mentioned fish is available, LC-MS/MS analysis was performed on two Seriola spp. caught in the same area in 2009 and revealed levels of CTXs above the EU regulatory limits (). In 2009, in the port of Hamburg (Germany), 15 sailors presented gastrointestinal or neurological symptoms after having eaten fish (Caranx sexfasciatus and Cephalopholis miniata) caught in the Caribbean. The presence of CTXs in the fish was confirmed through LC-MS/MS analysis performed
Figure A.1: Plot depicting (A) forward-scatter vs. side-scatter and (B) fluorescent PE-Cy5.5 channel vs. side-scatter during Flow Assisted Cell Sorting (FACS) of ALP2 microalgae. Figure A.2: UV-Vis multi-wavelength absorbance spectra of ALP2 methanol extracts.